Barr Pharmaceuticals (BRL) Receives Approval for Generic Aredia
More News related to BRL
- FDA Approves Duramed's Synthetic Conjugated Estrogens-A Vaginal Cream
- Barr Confirms Patent Challenge of Amrix(R) Extended-Release Capsules, 15mg & 30mg
- Cephalon (CEPH) and Eurand (EURX) File Infringement Suit Against Mylan (MYL) and Barr Pharma (BRL)
- Watson Pharmaceuticals (WPI) Agrees to Acquire Portfolio of Generic Pharma Products Following Teva/Barr Merger
- Barr (BRL) Shareholders Approval Proposed Acquisition of Teva (TEVA)
More News related to PFE
- Cramer Says Pfizer (PFE) Should Buy Allergan (AGN)
- Pfizer (PFE) Announces Results of Lipitor Study
- Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows
- Pfizer's Novel HIV/AIDS Treatment SELZENTRY(TM) Becomes the Latest Fully Approved Antiretrovial for Treatment-Experienced HIV Patients
- Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: NVS, JNJ, PFE, GSK, ABT, AZN
More News related to FDA
- After-Hours Movers 12/03: Adobe (ADBE) Lower on Guidance; Enzon (ENZN) Up on Debt Pay down
- Trading Radar for 12/04: UTi Worldwide (UTIW), Wind River (WIND), Magma Design (LAVA) Report; Initial Jobless Claims, Factory Orders Due
- Unusual 11 Mid-Day Movers 12/03: OGXI, PPO, BZH, GW Higher; IFX, HSNI, FCX, PALM Lower
- Notable Analyst Rating Changes 12/03: LMT, DRI, CTAS Upgraded; ALO, SYK, FSLR Downgraded
- Morning Movers 12/03: Constellation Energy (CEG) Jumps On Alternative Bid From EDF, Schlumberger (SLB) Down On Warning
Barr Pharmaceuticals, Inc. (NYSE: BRL) announced that its subsidiary, PLIVA - Lachema a.s., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pfizer Inc.'s (NYSE: PFE) Aredia (pamindronate disodium) Injection, 30mg/mL, 60mg/mL, and 90mg/mL. The Company plans to launch its product in the fourth quarter of calendar 2008. With this approval, Barr's U.S. generic injectable portfolio now totals eight products.
Barr's generic Aredia (pamindronate disodium) product will compete in a market that had total annual sales of approximately $21 million for the twelve months ended June 2008, based on IMS sales data.[SM]
Related Categories
FDAStocks Mentioned
+0.79Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
